CIK 0001725160
- Non-accelerated filer
- Smaller reporting company
Zentalis Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ZNTL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823607803
- Phone
- +1 858-263-4333
- Business address
- 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- Zentalis Pharmaceuticals, LLC, Zeno Pharma, LLC
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 57,603 shares (grant or award)
- 4 Grant or award Director acquired 57,603 shares (grant or award)
- 4 Grant or award Director acquired 57,603 shares (grant or award)
- 4 Grant or award Director acquired 57,603 shares (grant or award)
- 4 Grant or award Director acquired 57,603 shares (grant or award)
- 4 Open-market buy Director bought 21,000 shares at $1.40 ($29,373)
- 4 Open-market buy Chief Medical Officer bought 20,000 shares at $2.28 ($45,656)
- 4 Open-market sale PAO and Interim PFO sold 2,615 shares at $1.71 ($4,476)
- 4 Open-market sale Chief Scientific Officer sold 14,368 shares at $1.71 ($24,591)
- 4 Open-market sale Chief Legal Officer sold 13,230 shares at $1.71 ($22,643)
- 4 Grant or award Chief Medical Officer acquired 16,629 shares (grant or award)
- 4 Grant or award CEO & President acquired 59,388 shares (grant or award)
- 4 Open-market buy Director bought 60,000 shares at $1.72 ($103,446)
- 4 Open-market buy Director bought 14,200 shares at $1.76 ($24,966)
- 4 Open-market buy CEO & President bought 28,500 shares at $1.73 ($49,345)
- 4 Open-market sale Chief Scientific Officer sold 4,411 shares at $3.12 ($13,762)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 2 of 13 · 252 filings